Professional Role and Responsibilities
Anna Malmgren is currently serving as Vice President (VP) and Head of Projects, Early Respiratory & Immunology, within the BioPharmaceuticals R&D division at AstraZeneca, based in Gothenburg, Sweden. She leads a dynamic Respiratory & Immunology group focused on strategy and execution of global drug development projects targeting respiratory and immunological diseases. Her role involves significant responsibilities in early clinical development, including conceptualization, project administration, and cross-functional leadership across multiple projects. Anna holds senior director level accountability for global drug projects aiming at novel treatments in these therapeutic areas.
Industry Experience and Expertise
With over 20 years of experience in the pharmaceutical industry, Anna possesses a robust skill set including:
- Clinical development and clinical research management
- Good Clinical Practice (GCP) and pharmacology
- Cross-functional team leadership and project administration
Her background includes a Postgraduate Certificate in Clinical Research (Executive) from Cranfield University, UK (2012-2014), supporting her clinical and project leadership capabilities.
Scientific Contributions and Publications
Anna Malmgren has contributed extensively to the scientific literature, particularly in the respiratory and immunology fields, with notable involvement in:
- Early development of inhaled ENaC inhibitors (e.g., AZD5634), characterized in multiple phase I clinical studies involving healthy subjects and patients, showing extended lung retention and improved safety profiles relative to previous compounds. She was credited with conceptualization, project administration, and manuscript editing for these studies.
- Research relating to CXCR2 antagonists (e.g., AZD5069) focused on neutrophil-related pathways central to respiratory inflammation, contributing to drug safety and efficacy evaluations.
- Multiple publications and project leadership roles in asthma subtypes, including T2-low asthma, and cystic fibrosis therapeutic development.
- Participation in exploratory and preclinical studies advancing respiratory and inflammatory disease treatments, frequently acknowledged in peer-reviewed journals such as Journal of Cystic Fibrosis and Frontiers in Immunology.
Her scientific productivity is quantitatively ranked among AstraZeneca scientists with an i10-index of approximately 25, indicating at least 25 publications cited ten or more times.
Company Context and Strategic Focus
AstraZeneca’s BioPharmaceutical R&D unit in Gothenburg, where Anna operates, is a hub for innovation in respiratory, inflammation, and autoimmune diseases. The company’s focus on precision medicine infrastructure and the development of novel therapeutics aligns directly with Anna’s leadership role in early clinical projects.
Recent recruitment and team-building announcements from Anna emphasize:
- A drive to expand the Respiratory & Immunology team globally, seeking experienced project leaders and directors to advance pipeline candidates.
- Strategic prioritization of early-stage global drug projects within respiratory diseases, signaling active pipeline expansion and innovation under her guidance.
Geographic and Professional Network
Anna operates primarily out of Greater Gothenburg Metropolitan Area, Sweden, a key site for AstraZeneca’s respiratory and immunology therapeutic development. Her LinkedIn presence shows active engagement in industry hiring initiatives and professional networking, reinforcing her leadership status in the field.
Summary
Anna Malmgren is a senior pharmaceutical executive with deep expertise in early clinical development for respiratory and immunology drug projects at AstraZeneca. Her leadership extends to global strategic execution and project administration, underpinned by a strong academic and scientific publication record. Her group is actively recruiting and expanding in alignment with AstraZeneca’s broader R&D goals, reflecting a vibrant development pipeline focused on innovative therapies in respiratory and inflammatory diseases. This profile indicates that Anna is a key decision-maker and influencer in AstraZeneca’s early-stage respiratory and immunology portfolio, with insights into clinical program strategy, patient populations, and drug candidate progression.
